Small molecule compounds targeting the p53 pathway: Are we finally making progress?

Apoptosis

Volumn 19, Issue 7, 2014, Pages 1055-1068

  Yu, Xin ^a   Narayanan, Sumana ^a   Vazquez, Alexei ^a   Carpizo, Darren R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Mutant; p53; Reactivation; Small molecule compound; Wild type

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAZOLE DERIVATIVE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NUTLIN; NUTLIN 3; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX INHIBITOR; PROTEIN P53; PUMA PROTEIN; SERDEMETAN; TENOVIN 1; TENOVIN 6; TETRACYCLINE; THIOSEMICARBAZONE DERIVATIVE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

ANAEROBIC GLYCOLYSIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; DNA BINDING; DNA CONFORMATION; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DRUG SCREENING; EPITHELIUM CELL; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GLYCOLYSIS; HEAT SHOCK RESPONSE; HUMAN; LYMPHOCYTE; MACROMOLECULE; MELANOMA CELL LINE; METABOLIC STRESS; MISSENSE MUTATION; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; TISSUE SPECIFICITY; UBIQUITINATION; WHOLE BODY RADIATION; CELL PROLIFERATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR LIBRARY; MUTATION; NEOPLASMS; PHARMACOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902532968     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-0990-3     Document Type: Article

References (117)

1. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
2. Joensuu H (2012) Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 9:351-358
3. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
4. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749-758
5. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
6. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604 (Pubitemid 37328926)
7. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945-8951 (Pubitemid 30180252)
8. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299 (Pubitemid 27220766)
9. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189 (Pubitemid 27429621)
10. Li D, Marchenko ND, Schulz R et al (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Molecular cancer research : MCR 9:577-588
11. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127:1323-1334 (Pubitemid 44960417)
12. Ventura A, Kirsch DG, McLaughlin ME et al (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-665 (Pubitemid 46232887)
13. Xue W, Zender L, Miething C et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656-660 (Pubitemid 46232886)
14. Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788-6793 (Pubitemid 32059139)
15. Olive KP, Tuveson DA, Ruhe ZC et al (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860 (Pubitemid 40017690)
16. Adorno M, Cordenonsi M, Montagner M et al (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87-98
17. Dittmer D, Pati S, Zambetti G et al (1993) Gain of function mutations in p53. Nat Genet 4:42-46 (Pubitemid 23165910)
18. Liu G, McDonnell TJ, de Oca Montes, Luna R et al (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174-4179 (Pubitemid 30226106)
19. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99 (Pubitemid 30113711)
20. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13:927-934
21. Danovi D, Meulmeester E, Pasini D et al (2004) Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24:5835-5843 (Pubitemid 38787968)
22. Kleiblova P, Shaltiel IA, Benada J et al (2013) Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. Journal Cell Biol 201:511-521
23. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2:a001222
24. Bouchet BP, Caron de Fromentel C, Puisieux A, Galmarini CM (2006) p53 as a target for anti-cancer drug development. Crit Rev Oncol/Hematol 58:190-207 (Pubitemid 43796080)
25. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360-10365
26. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103:15056-15061 (Pubitemid 44583163)
27. Wassman CD, Baronio R, Demir O et al (2013) Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 4:1407
28. Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268-1286
29. Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 103:11003-11008 (Pubitemid 44148408)
30. Kravchenko JE, Ilyinskaya GV, Komarov PG et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 105:6302-6307 (Pubitemid 351758341)
31. Bykov VJ, Issaeva N, Shilov A et al (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288 (Pubitemid 34250107)
32. Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21:614-625
33. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823
34. Ikediobi ON, Davies H, Bignell G et al (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606-2612 (Pubitemid 44848987)
35. Peltonen K, Colis L, Liu H et al (2010) Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5:e12996
36. Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res 2:20-28
37. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9:862-873
38. Chen L, Agrawal S, Zhou W, Zhang R, Chen J (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 95:195-200 (Pubitemid 28103930)
39. Wasylyk C, Salvi R, Argentini M et al (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18:1921-1934 (Pubitemid 29150079)
40. Tortora G, Caputo R, Damiano V et al (2000) A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 88:804-809
41. Mendrysa SM, O'Leary KA, McElwee MK et al (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20:16-21 (Pubitemid 43042663)
42. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23-31
43. Kussie PH, Gorina S, Marechal V et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953 (Pubitemid 26398409)
44. Ding K, Lu Y, Nikolovska-Coleska Z et al (2005) Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 127:10130-10131 (Pubitemid 41045454)
45. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848 (Pubitemid 38174664)
46. Tovar C, Rosinski J, Filipovic Z et al (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-1893 (Pubitemid 43228788)
47. Tovar C, Graves B, Packman K et al (2013) MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73:2587-2597
48. Saha MN, Qiu L, Chang H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23
49. Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53-62
50. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223-241
51. Zou P, Zheng N, Yu Y et al (2012) Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci 15:265-280
52. Ding K, Lu Y, Nikolovska-Coleska Z et al (2006) Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49:3432-3435 (Pubitemid 43902447)
53. Issaeva N, Bozko P, Enge M et al (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328 (Pubitemid 40022713)
54. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA (2005) NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 11:1135-1136 author reply 1136-1137
55. Saha MN, Jiang H, Yang Y et al (2012) Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 7:e30215
56. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9:1847-1855
57. Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM (2012) The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 325:35-41
58. Kojima K, Burks JK, Arts J, Andreeff M (2010) The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 9:2545-2557
59. Smith MA, Gorlick R, Kolb EA et al (2012) Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 59:329-332
60. Chargari C, Leteur C, Angevin E et al (2011) Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett 312:209-218
61. Tabernero J, Dirix L, Schoffski P et al (2011) A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res 17:6313-6321
62. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299-309
63. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG (2003) Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 278:38315-38324 (Pubitemid 37221723)
64. Wang X, Wang J, Jiang X (2011) MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 286:23725-23734
65. Huang L, Yan Z, Liao X et al (2011) The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 108:12001-12006
66. Vassilev LT (2005) p53 Activation by small molecules: application in oncology. J Med Chem 48:4491-4499
67. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM (2006) Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281:33036-33044 (Pubitemid 46036686)
68. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810-8817 (Pubitemid 47437457)
69. Reed D, Shen Y, Shelat AA et al (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285:10786-10796
70. Graves B, Thompson T, Xia M et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 109:11788-11793
71. Wang H, Yan C (2011) A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13:611-619
72. Lain S, Hollick JJ, Campbell J et al (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454-463 (Pubitemid 351609441)
73. Gudkov AV, Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117-129 (Pubitemid 37328879)
74. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23:462-472
75. Canner JA, Sobo M, Ball S et al (2009) MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101:774-781
76. Graat HC, Carette JE, Schagen FH et al (2007) Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6:1552-1561 (Pubitemid 46954022)
77. Aziz MH, Shen H, Maki CG (2011) Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 30:4678-4686
78. Mirzayans R, Andrais B, Scott A, Murray D (2012) New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012:170325
79. Cheok CF, Dey A, Lane DP (2007) Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 5:1133-1145 (Pubitemid 350137109)
80. Levine AJ, Wu MC, Chang A et al (1995) The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 768:111-128
81. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614 (Pubitemid 34556481)
82. Selivanova G, Wiman KG (2007) Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26:2243-2254 (Pubitemid 46536645)
83. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510
84. Haupt S, Haupt Y (2004) Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin Cancer Biol 14:244-252 (Pubitemid 38824585)
85. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129 (Pubitemid 34311366)
86. Lambert JM, Gorzov P, Veprintsev DB et al (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376-388
87. Lehmann S, Bykov VJ, Ali D et al (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30:3633-3639
88. Bykov VJ, Issaeva N, Zache N et al (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384-30391 (Pubitemid 41216221)
89. Wiman KG (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29:4245-4252
90. Liu X, Wilcken R, Joerger AC et al (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034-6044
91. Puca R, Nardinocchi L, Porru M et al (2011) Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10:1679-1689
92. Yu Y, Kalinowski DS, Kovacevic Z et al (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52:5271-5294
93. Terzian T, Suh YA, Iwakuma T et al (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337-1344 (Pubitemid 351717524)
94. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441-464
95. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703-707
96. DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345-19350
97. Choudhury AR, Ju Z, Djojosubroto MW et al (2007) Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 39:99-105 (Pubitemid 46026508)
98. Michalak EM, Villunger A, Adams JM, Strasser A (2008) In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15:1019-1029 (Pubitemid 351712606)
99. Li T, Kon N, Jiang L et al (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269-1283
100. Blagosklonny MV (2012) Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) 4:450-455
101. Blagosklonny MV (2012) Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 4:159-165
102. Feng Z, Hu W, de Stanchina E et al (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67:3043-3053 (Pubitemid 46724841)
103. Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204-8209 (Pubitemid 40800067)
104. Matthew EM, Hart LS, Astrinidis A et al (2009) The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 8:4168-4175
105. Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451-460
106. Janes MR, Fruman DA (2010) Targeting TOR dependence in cancer. Oncotarget 1:69-76
107. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430 (Pubitemid 44050136)
108. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18:617-633
109. Vousden KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9:691-700
110. Matoba S, Kang JG, Patino WD et al (2006) p53 regulates mitochondrial respiration. Science 312:1650-1653 (Pubitemid 43902663)
111. Cheung EC, Athineos D, Lee P et al (2013) TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 25:463-477
112. Gottlieb E, Vousden KH (2010) p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2:a001040
113. Maddocks OD, Berkers CR, Mason SM et al (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493:542-546
114. Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drugmetformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752 (Pubitemid 47105521)
115. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 107:7455-7460
116. Desilet N, Campbell TN, Choy FY (2010) p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol 12:143-146
117. Brooks CL, Gu W (2008) p53 Activation: a case against Sir. Cancer Cell 13:377-378 (Pubitemid 351609448)